Clinical Trial Results:
Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma
Summary
|
|
EudraCT number |
2011-004593-29 |
Trial protocol |
DE |
Global end of trial date |
29 Jun 2023
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
03 Jan 2024
|
First version publication date |
03 Jan 2024
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
Uni-Koeln-1495
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02641314 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
University of Cologne
|
||
Sponsor organisation address |
Albertus-Magnus-Platz, Cologne, Germany, 50923
|
||
Public contact |
Neuroblastomstudie, Children’s Hospital, University of Cologne, +49 2214786853, neuroblastomstudie@uk-koeln.de
|
||
Scientific contact |
Neuroblastomstudie, Children’s Hospital, University of Cologne, +49 2214786853, neuroblastomstudie@uk-koeln.de
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Interim
|
||
Date of interim/final analysis |
10 Apr 2019
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
29 Jun 2023
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary trial objective is to demonstrate the non-inferiority of event free survival (EFS) in children and adolescents ≥ 2 and < 21 years of age with recurrent or progressive high risk neuroblastoma treated with low toxic metronomic celecoxib therapy in combination with low-dose metronomic cyclophosphamide, etoposide and vinblastine in comparison to a historical control group. Event free survival (EFS) defined as time from start of treatment up to: Progression (emerged from residual tumor, PD) or recurrence (developing from CR achieved by metronomic treatment), drop-out for unacceptable toxicity, secondary malignant neoplasm or death of any reason
|
||
Protection of trial subjects |
No relevant toxicities. No toxic deaths related to the metronomic treatment. No change of risk-benefit balance.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Dec 2015
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 18
|
||
Worldwide total number of subjects |
18
|
||
EEA total number of subjects |
18
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
13
|
||
Adolescents (12-17 years) |
1
|
||
Adults (18-64 years) |
4
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
18 of a maximum of 26 patients have been recruited in 5 of 8 national test center in Germany. | ||||||
Pre-assignment
|
|||||||
Screening details |
1 screening failure | ||||||
Period 1
|
|||||||
Period 1 title |
Treatment (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Metronomic treatment | ||||||
Arm description |
The trial schedule consists of continuously administered cycles of metronomic therapy over 364 days. Treatment consists of eight alternating 28-day cycles of PCCVE and PCCV followed by five cycles PCCV. Vinblastine will be given every second week. Etoposide is only given in cycle PCCVE (cycle 1, 3, 5, 7). The PCCVE cycle consists of propranolol, celecoxib, cyclophosphamide, vinblastine, and etoposide. On the first day of the very first PCCVE cycle, one single intravenous infusion of cyclophosphamide loading dose (500 mg/m2 i.v., duration 1 hour) is given. The PCCV cycle consists of propranolol, celecoxib, cyclophosphamide, and vinblastine. | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Propranolol
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Tablet
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Propranolol
cycle 1:
0.5 mg/kgxd p.o. day 1,
1 mg/kgxd p.o. day 2,
2 mg/kgxd p.o. day 3-28;
all further cycles:
2 mg/kgxd p.o., day 1 – 28
(maximum total daily dose: 120 mg)
divided in 2 doses per day
|
||||||
Investigational medicinal product name |
Celecoxib
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Tablet
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
400 mg/m2xd p.o.; day 1-28
(maximum total daily dose: 800 mg)
divided in 2 doses per day
|
||||||
Investigational medicinal product name |
Cyclophosphamide
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Capsule, Solution for injection/infusion
|
||||||
Routes of administration |
Oral use, Infusion
|
||||||
Dosage and administration details |
cycle 1, day 1:
loading dose: 500 mg/m2 intravenous 1-h-infusion,
single dose
cycle 1, day 2-28; all further cycles day 1-28:
25 mg/m2xd p.o
(maximum total daily dose: 50 mg)
as single daily dose
|
||||||
Investigational medicinal product name |
Etoposide
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Capsule
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
25 mg/m2xd p.o.; day 1-21
(maximum total daily dose: 50 mg)
as single daily dose
|
||||||
Investigational medicinal product name |
Vinblastine
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Solution for injection/infusion
|
||||||
Routes of administration |
Infusion
|
||||||
Dosage and administration details |
3 mg/m2xd i.v.
(maximum total daily dose: 6 mg)
administered day 1 and 15 (every two weeks)
as single daily dose
|
||||||
|
|
||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment
|
|||||||||||||||||||||||||||||||||
Reporting group description |
11 | |||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Metronomic treatment
|
||
Reporting group description |
The trial schedule consists of continuously administered cycles of metronomic therapy over 364 days. Treatment consists of eight alternating 28-day cycles of PCCVE and PCCV followed by five cycles PCCV. Vinblastine will be given every second week. Etoposide is only given in cycle PCCVE (cycle 1, 3, 5, 7). The PCCVE cycle consists of propranolol, celecoxib, cyclophosphamide, vinblastine, and etoposide. On the first day of the very first PCCVE cycle, one single intravenous infusion of cyclophosphamide loading dose (500 mg/m2 i.v., duration 1 hour) is given. The PCCV cycle consists of propranolol, celecoxib, cyclophosphamide, and vinblastine. | ||
Subject analysis set title |
Full dataset analysis
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
All patients enrolled into the study.
|
||
Subject analysis set title |
Population for sensitivity analysis
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
patients who fulfilled the inclusion and exclusion criteria, have been registered in the study, and were treated conform to the protocol.
|
||
Subject analysis set title |
Population for safety analysis
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
All patients who entered the study and received at least the medication of the first day of the first treatment cycle.
|
|
|||||||||||||
End point title |
Events [1] | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
until 30 days after the last treatment of the last patient
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The final stastical analysis is ongoing. Values will be updated once the analysis is completed. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||
Adverse events information [1]
|
|||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
until 30 days after the last trial medication of the last patient
|
||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||
Dictionary name |
CTCAE | ||||||||||||||||||||||||||||||||||||||||
Dictionary version |
4.03
|
||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Population for safety analysis
|
||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients reported with serious adverse events | ||||||||||||||||||||||||||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: Final analysis of adverse events is ongoing. Values will be updated once the analysis is completed. |
|||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
28 Aug 2017 |
METRO-NB2012 Trial Protocol Amendment Version 3.5.4 |
||
09 Mar 2020 |
METRO-NB2012 Trial Protocol Amendment Version 3.5.6 |
||
05 May 2021 |
METRO-NB2012 Trial Protocol Amendment 4.0 |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |